Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)
14 janv. 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system)...
Scilex Announces Addition of ZTlido® to Express Scripts National Formularies
14 janv. 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido®...
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
10 sept. 2018 04h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”),...